Udhayvir Grewal Shares New Article on HER2 Prognostic Impact in mCRC
Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared a post on X about a recent article by Marco Maria Germani and colleagues:
“Largest pooled RCT analysis (N=1,604; TRIBE2, TRIPLETE, VALENTINO, ATEZOTRIBE, PANDA, PANAMA, PARADIGM, CALGB/SWOG80405) confirms their negative prognostic impact of HER2 alterations in mCRC no predictive role for biologics.
HER2 amplification/over-expression (~5%): shorter PFS (9.8 vs 12.2 mo; HR 1.31, p=.02) and OS (28.0 vs 34.9 mo; HR 1.37, p=.01), similar ORR (75% vs 72%).
HER2 mutations (~2%): shorter OS (23.7 vs 34.4 mo; HR 1.56, p=.04), no differential benefit from anti-EGFR or bevacizumab.
In left-sided HER2+ tumors, outcomes were similar with chemo+bevacizumab vs chemo+anti-EGFR.
Takeway:
HER2 status is a negative prognostic factor in pMMR/MSS RAS/BRAF WT mCRC. It should not guide the frontline choice between anti-vascular vs anti-EGFR therapy.
Does this change practice for you?”
Title: Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Authors: Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Francesca Battaglin, Francesca Bergamo, Lisa Salvatore, Arndt Stahler, Carlotta Antoniotti, Kohei Shitara, Alan Venook, Eiji Oki, Kei Muro, Clara Ugolini, Junpei Soeda, Sara Lonardi, Filippo Pietrantonio, Heinz-Josef Lenz, Dominik Paul Modest, Takayuki Yoshino, Chiara Cremolini
Read the Full Article in ASCO Publications.
More posts featuring Udhayvir Grewal on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023